A qualitative study of the use of a clinical decision support tool in pediatric diarrhea identified the expectations of clinicians and the concerns of parents surrounding the tool’s use. “Clinical ...

FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.

Thanks to COVID-era discussions, the 2023 coverage of a Delta passenger who had diarrhea in their seat (I cannot imagine), ...

Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr. Michelle Barron, UCHealth’s senior medical director of infection prevention and ...

The FDA has approved linaclotide (Linzess) capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation, according to a Nov. 5 news release. Linzess is the first ...

Initially approved in 2012, linaclotide is already indicated for treating chronic idiopathic constipation and IBS-C in adults. The FDA in 2023 also approved linaclotide capsules for treating ...

The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...

The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...